Detralex pills p/o 1000mg №9×2

Name:
Detralex tab. p / captive ob. 1000mg No. 9×2
Description:
Orange-pink film-coated tablets, oval, scored on both sides; type of tablet on a break – from pale yellow to yellow, heterogeneous structure. The main active ingredient is a purified micronized flavonoid fraction (diosmin + flavonoids expressed as hesperidin) type of tablet on a break – from pale yellow to yellow, heterogeneous structure. 1 tab. purified, micronized flavonoid fraction 1000 mg, incl. diosmin 900 mg (90%) flavonoids in terms of hesperidin 100 mg (10%) Excipients: purified water – 40 mg, gelatin – 62 mg, magnesium stearate – 8 mg, microcrystalline cellulose – 124 mg, sodium carboxymethyl starch type A – 54 mg, talc – 12 mg. Tablet core weight: 1340 mg*. The composition of the film shell: sodium lauryl sulfate – 0.13 mg, premix for an orange-pink film shell OY-S-8761 (glycerol – 1.628 mg, hypromellose – 27.039 mg, macrogol 6000 – 0.651 mg, magnesium stearate – 1.628 mg, iron oxide dye red – 0.211 mg, titanium dioxide – 5.205 mg, iron dye yellow oxide – 0.633 mg). Tablet polishing excipient: macrogol 6000 – 1.3 mg. Film-coated tablet weight: 1378.425 mg. 9 pcs. – blisters (2) – packs of cardboard with the control of the first opening (if necessary). 9 pcs. – blisters (3) – packs of cardboard with the control of the first opening (if necessary). 10 pieces. – blisters (3) – packs of cardboard with the control of the first opening (if necessary). 10 pieces. – blisters (6) – packs of cardboard with control of the first opening (if necessary). * Given the average moisture content of the purified, micronized flavonoid fraction – 4% (or 40 mg per tablet), the amount of substance per tablet – 1040 mg. Dosage The drug is administered orally. Tablets should be swallowed with water. The line on the tablet is intended solely for division in order to facilitate swallowing. The recommended dose for venous-lymphatic insufficiency is 1 tablet / day, preferably in the morning, during a meal. The duration of the course of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated. The recommended dose for acute hemorrhoids is 3 tablets / day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets / day (1 tablet in the morning and evening) for the next 3 days. The recommended dose for chronic hemorrhoids is 1 tab./day. Special instructions Before starting the use of the drug Detralex®, the patient is advised to consult a doctor. With an exacerbation of hemorrhoids, the appointment of Detralex® does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in the “Dosage regimen” section. In the event that the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist who will select further therapy. In the presence of venous circulation disorders, the maximum effect of treatment is provided by a combination of therapy with a healthy (balanced) lifestyle: it is desirable to avoid prolonged exposure to the sun, prolonged stay on the legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings improves blood circulation. The patient should immediately consult a doctor if the condition worsens or does not improve during treatment. Influence on the ability to drive vehicles and control mechanisms Clinical studies to study the effect of the drug Detralex® on the ability to drive a car and perform work requiring a high rate of mental and physical reactions have not been conducted. However, based on the available safety data, it can be concluded that Detralex® does not affect (has no significant effect) on these processes. Pharmacological actionDetralex® has venotonic and angioprotective properties. The drug reduces vein extensibility and venous congestion, reduces capillary permeability and increases their resistance. The results of clinical studies confirm the pharmacological activity of the drug in relation to venous hemodynamic parameters. A statistically significant dose-dependent effect of Detralex® was demonstrated for the following venous plethysmographic parameters: venous capacity, venous distensibility, venous emptying time. The optimal dose-effect ratio is observed when taking 1000 mg per day. Detralex® increases venous tone: using venous occlusive plethysmography, a decrease in venous emptying time has been shown. In patients with signs of severe microcirculation disorders, after therapy with Detralex®, there is a (statistically significant compared with placebo) increase in capillary resistance, assessed by angiostereometry. The therapeutic efficacy of Detralex® has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids. Pharmacokinetics Metabolism The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine. Excretion Excreted from the body mainly with feces. With urine, on average, about 14% of the amount of the drug taken is excreted. T1 / 2 is 11 hours. Indications for use Detralex® is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms). Therapy of symptoms of venous-lymphatic insufficiency: pain; cramps of the lower extremities; feeling of heaviness and fullness in the legs; leg fatigue. Therapy of manifestations of venous-lymphatic insufficiency: swelling of the lower extremities; trophic changes in the skin and subcutaneous tissue; venous trophic ulcers. Symptomatic therapy of acute and chronic hemorrhoids Dosage and administration The drug is administered orally. Tablets should be swallowed with water. The line on the tablet is intended solely for division in order to facilitate swallowing. The recommended dose for venous-lymphatic insufficiency is 1 tablet / day, preferably in the morning, during a meal. The duration of the course of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated. The recommended dose for acute hemorrhoids is 3 tablets / day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets / day (1 tablet in the morning and evening) for the next 3 days. The recommended dose for chronic hemorrhoids is 1 tab./day. Use during pregnancy and lactation Pregnancy In experimental studies on animals, teratogenic effects have not been identified. To date, there have been no reports of adverse effects when using the drug in pregnant women. Breast-feeding Due to the lack of data on the excretion of the drug with breast milk, lactating women are not recommended to take the drug. Effects on reproductive function Reproductive toxicity studies have shown no effect on reproductive function in rats of both sexes. Interaction with other drugs Clinical studies on the interaction of the drug Detralex® with other drugs have not been conducted. To date, no cases of drug interactions have been reported. Contraindications Hypersensitivity to the active ingredients or excipients that make up the drug. The drug is not recommended for lactating women. Composition 9 pcs. – blisters (2) – packs of cardboard with the control of the first opening (if necessary). Overdose No cases of overdose have been described. In case of an overdose of the drug, the patient should immediately seek medical help. Side effects Side effects of the drug Detralex®, observed during clinical trials, were mild. Gastrointestinal disorders (diarrhea, dyspepsia, nausea, vomiting) were predominantly noted. While taking the drug Detralex®, the following side effects were reported in the form of the following gradation: very often (? 1/10), often (? 1/100, <1/10), infrequently (? 1/1000, <1/100) , rare (?1/10,000, <1/1000), extremely rare (<10,000), unspecified frequency (frequency cannot be calculated from the available data). From the side of the central nervous system: rarely - dizziness, headache, general malaise. From the gastrointestinal tract: often - diarrhea, dyspepsia, nausea, vomiting; infrequently - colitis; unspecified frequency - abdominal pain. From the skin: rarely - rash, itching, urticaria; unspecified frequency - isolated swelling of the face, lips, eyelids; in exceptional cases - angioedema. The patient should be informed that when any, incl. not mentioned in the instructions, adverse reactions and sensations, as well as changes in laboratory parameters, should be reported to the doctor. Storage conditions The drug should be stored out of the reach of children at a temperature not exceeding 30 ° C. Buy Detralex tablets p / o 1000 mg No. 9x2